1. 11 B169-0313 Assistance ventriculaire Les produits en développement Pr Camille Dambrin Service de chirurgie cardio-vasculaire, CHU Toulouse-Rangueil

2. 2 B169-0313 Lead the use of Mechanical Circulatory Support (MCS) to dramatically improve outcomes for patients with advanced heart failure  Continual improvement of clinical outcomes  Transparent, rigorous clinical research  Increasing awareness and education  Technology innovation leadership Market leadership across the spectrum of MCS Vision for and commitment to the future of MCS Our Values / Our Commitments Thoratec Corporation

3. 3 3 Assistance à court terme Acute/Internediate Support

4. 4 B169-0313 CentriMag ® Acute/Internediate Support

5. 5 B169-0313 CentriMag Recent Additions 2nd Gen Console Surgical Cannulae System Cart Transporter Available Acute/Internediate Support

6. 6 B169-0313 HeartMate PHP® *In development. Not approved for clinical use Acute/Internediate Support

7. 7 B169-0313 Cardiac Catheter Pump Low-profile percutaneous device delivered through 13F sheath Expands to 24F across aortic valve Designed to deliver over 4 lpm for up to 10 days Cardiac Catheter Pump Low-profile percutaneous device delivered through 13F sheath Expands to 24F across aortic valve Designed to deliver over 4 lpm for up to 10 days HeartMate PHP* *In development. Not approved for clinical use Target Applications Acute MI Cardiogenic Shock High-risk PCI Acutely decompensated heart failure Acute/Internediate Support

8. 8 8 Assistance à long terme Chronic Support

9. 9 B169-0313 Chronic Support

10. 10 B169-0313 Power Unit Evolution Chronic Support

11. 11 Mobile Power Unit (MPU)* Enhanced Functionality Easier patient management (1,3 kg) Improved mobility and cable management Low maintenance (only AAA batteries) Long cable (6,4m) Safety Design Echoes System Controller alarms (even if power is lost) Internal Diagnostics Improved durability Twist resistant cables Commercial use targeted for june 2015 Designing for Portable and Patient-Friendly VAD Power Expected Benefits Program Status Chronic Support

12. 12 B169-0313 HeartMate II System Chronic Support

13. 13 HeartMate ® III with Full MagLev™ Designed with a Healthy Respect for the Blood *Caution: Investigational device. Limited by Federal US law to investigational use Chronic Support

14. 14 B169-0313 What is Full MagLev? Uses magnets to support all six degrees of freedom of the rotor, such that the rotor remains essentially fixed except for rotation. (Doesn’t use physical or hydrodynamic/blood bearings) Chronic Support

15. 15 B169-0313 HeartMate III*: Full MagLev™ Technology Key Design Features: Large and Consistent Gaps (Designed to minimize Shear Stress and Blood Component Activation) – HeartMate III secondary flow paths are ~0.5 mm along the side, and ~1.0 mm pump above and below the rotor. – Conversely, hydrodynamic bearings are typically operated with much smaller gaps, 0.05 of a millimeter or so. – HeartMate III pump surfaces are flat and flow is undisturbed; wedging surfaces and other features required for hydrodynamic bearings are not required. ~ 0.5 mm along the side ~ 1.0 mm top and bottom Chronic Support

16. 16 B169-0313 How much difference is there? From a Red Blood Cell’s Point of View Gap Size# of Red Blood Cells Full MagLev1,000μm167 Hydrodynamic Bearing50μm8 6-8 μm Stacked RBCs Chronic Support

17. 17 B169-0313 HeartMate III*: Full MagLev Technology Key Design Feature: Pulsatility (Minimize stasis) These large gaps also enable the rapid speed changes used by our artificial pulse feature without rotor/housing contact. Some potential benefits: Designed to promote washing of the pump Prevents the formation of zones of recirculation and stasis. Zero Net Change in Flow Speed ramps up and down (zero net change) Potential Clinical Benefits 1-3 For example, a theorized source of bleeding in chronic support with constant-speed rotary pumps involves the development of arteriovenous malformations, a syndrome associated with persistently low pulse pressure 0.15 2.00 FS 0.20 FS-2000 FS+2000 time [ s ] rotor speed [ rpm ] 1.Tsai H. S., et al. Semin Thromb Hemost 2003;29(5):479-88. 2.Malehsa D, Meyer AL, Bara C, Struber M. Eur J Cardiothorac Surg 2009;35:1091-3. 3.Crow S, John R, Boyle A, Shumway S, Liao K, Colvin-Adams M, Toninato C, Missov E, Pritzker M, Martin C, Garry D, Thomas W, Joyce L. J Thorac Cardiovasc Surg 2009;137:208-15. Chronic Support

18. 18 L’avenir The future

19. 19 B169-0313 HeartMate Fully Implanted System* (FILVAS) *In development. Not approved for clinical use MobileTetheredFree The future

20. 20 B169-0313 HeartMate Fully Implantable System* Flexible Lifestyle Eliminates the driveline and “around the clock” worn equipment. Forgiving Energy Transfer High-efficiency, user-friendly wireless energy transfer across a distance Designed for Advanced Implantation and Robust Battery Technology Custom battery technology tailored for implantable LVAD application – Expected to provide greater than 3 years of life with slow degradation Focus on reduced size and reliability of electronics Mobile Tethered Free Breakthrough technology to advance mechanical circulatory support. *In development. Not approved for clinical use The future

21. 21 B169-0313 Energy Efficiency and Patient Controller Miniaturized System Controller* Integrated on-board battery* *In development. Not approved for clinical use The future

22. 22 B169-0313 HeartMate X* *In development. Not approved for clinical use The future

23. 23 B169-0313 HeartMate ® X* Ultra-Compact, Highly Versatile VAD = New patient populations Potential to meet the needs of earlier stage patients Potential for minimally invasive implantation Potential for multiple configurations (LVAD, RVAD, BiVAD) Expected Benefits Features Utilizes proven HeartMate II bearing technology Partial to Full support (8 L/min) in ultra-compact size Highly energy efficient Miniaturized patient peripherals Left and/or right side assistance *In development. Not approved for clinical use The future

24. 24 B169-0313 Minimally Invasive and Multiple Configurations LVAD / RVAD / BiVAD *In development. Not approved for clinical use Partial support (design point: 2.5 L/min) Nominal full support (design point: 5.3 L/min) Right sided support (design point: 4.3 L/min) Designed for up to 8 L/min of flow The future

25. 25 B169-0313 Innovation: Saving More Lives Tomorrow A uniquely robust pipeline of new products HeartMate III* HeartMate X* HeartMate PHP* HeartMate IICentriMag HeartMate FILVAS* *In development. Not approved for clinical use